Merck has now moved from a scheduled earnings setup into a genuine live-results phase. On Tuesday, August 4, 2026, the company furnished a fresh SEC 8-K and second-quarter earnings release showing total worldwide sales of USD 16.6 billion, KEYTRUDA and KEYTRUDA QLEX sales of USD 8.4 billion, WINREVAIR sales of USD 588 million, and Animal Health sales of USD 1.8 billion.
Those facts matter because the quarter did not arrive as a simple large-cap pharma beat or miss. Merck also narrowed and raised its 2026 sales outlook to USD 66.3 billion to USD 67.3 billion, while a large Terns acquisition charge pushed the quarter to a GAAP loss per share of USD 0.54 and a non-GAAP loss per share of USD 0.13. For options traders, that creates a more useful post-results lesson than the earlier setup article alone could offer: the market now has to separate operating momentum from deal-related accounting distortion.
That is a distinct phase change from the site’s earlier Merck setup article, which focused on what MRK options might be pricing before the event. The market now has actual second-quarter product sales, updated company guidance, and a clearer view of how much the Terns transaction is complicating the EPS headline.
This article is for market commentary and options education only. This is not financial advice. Options trading involves risk and is not suitable for all investors. Review the site’s risk disclosure, the guide to how earnings affect options prices and implied volatility, the explainer on implied volatility (IV) in options trading: what it is and why it matters, and the primer on risk management in options trading: position sizing and probability.
What Merck actually reported
The most important confirmed facts from Merck’s August 4, 2026 results release were:
- Total worldwide sales were USD 16.6 billion, up 5% year over year, or 4% excluding foreign exchange.
- KEYTRUDA and KEYTRUDA QLEX sales were USD 8.4 billion, including USD 463 million from QLEX.
- WINREVAIR sales were USD 588 million, up 75% year over year.
- Animal Health sales were USD 1.8 billion, up 8% year over year, or 5% excluding foreign exchange.
- GARDASIL and GARDASIL 9 sales were USD 1.169 billion, up 4% year over year, or 3% excluding foreign exchange.
- Merck narrowed and raised its expected 2026 worldwide sales range to USD 66.3 billion to USD 67.3 billion.
- Merck now expects non-GAAP EPS to be between USD 2.66 and USD 2.76, with that outlook including charges tied to the Terns acquisition and related financing.
- For the quarter, GAAP EPS was a loss of USD 0.54 and non-GAAP EPS was a loss of USD 0.13 because of a USD 2.31 per-share charge for the Terns transaction.
Those details matter because they show a quarter where the operating story and the EPS headline moved in different directions. Sales and key growth products remained constructive, but acquisition accounting sharply changed how the earnings line looked.
Why this is a distinct event phase
Before the release, traders were still debating whether oncology strength, Winrevair uptake, Animal Health resilience, and older product pressure would keep the setup balanced. After the release, the debate changed:
- the sales base came in at USD 16.6 billion,
- KEYTRUDA and KEYTRUDA QLEX remained very large at USD 8.4 billion,
- Winrevair and Animal Health stayed meaningful growth contributors,
- GARDASIL improved rather than extending the weaker first-quarter vaccine frame,
- and management raised the full-year sales range even while deal charges distorted EPS.
That is enough to justify a related but distinct live-results article rather than treating August 4 as only a continuation of the August 3 setup story.
Why It Matters For Options Traders
1. Merck is now an operating-momentum versus charge-distortion story
The most useful post-results shift is that the market no longer has to guess whether Merck’s core business stayed firm in the quarter. The product-sales lines were constructive. The harder question is how much weight traders want to give the Terns charge when judging the stock immediately after earnings.
That matters for options because a stock can report strong underlying sales and still create a complicated event read if the headline EPS line looks weak. The options market now has to digest not only what Merck sold, but also how the accounting treatment changes the narrative that follows.
2. KEYTRUDA remains central, but the supporting cast matters more now
Merck is still heavily defined by KEYTRUDA, and the USD 8.4 billion quarterly figure confirms that. But the quarter did not stop there. WINREVAIR reached USD 588 million, Animal Health rose to USD 1.8 billion, and GARDASIL improved versus the year-ago quarter.
That matters because options traders should avoid reducing the whole event to one oncology number. A broader mix of contributors can make the post-earnings read more durable, especially if investors decide the business is carrying more than one growth engine while the company works through portfolio changes.
3. Raised sales guidance matters more than a superficial EPS read
Merck raised its expected worldwide sales range to USD 66.3 billion to USD 67.3 billion. That is a meaningful operating signal. At the same time, the company said its non-GAAP EPS outlook now includes substantial Terns-related charges and financing costs.
For options traders, that creates a cleaner educational point than a simple “beat” or “miss” label. The market may decide that the stronger sales frame is more important than the charge-heavy EPS presentation, or it may decide that acquisition-driven complexity deserves a lower confidence multiple in the near term. That tension is the real event.
4. The setup has shifted from anticipation into interpretation
The pre-event question was what Merck might say. The post-event question is how much of this combination was already in premium:
- strong oncology and newer-product momentum,
- a better full-year sales outlook,
- a less negative vaccine read than the first-quarter setup implied,
- and a charge-distorted EPS line that can confuse a quick reaction.
That is why this is an options-education event rather than a directional call. Traders now need to compare the realized move and volatility reset with the uncertainty that had been priced into the report.
Common misunderstandings and caveats
The GAAP loss means the operating quarter was weak
No. The release shows that the Terns acquisition charge played a major role in pushing quarterly EPS into a loss. The product-sales lines and the raised sales outlook point to a stronger operating picture than the headline EPS figure alone suggests.
KEYTRUDA is the only line that matters
Too simple. KEYTRUDA remains central, but WINREVAIR, Animal Health, and GARDASIL all changed the read of the quarter and the durability of the broader revenue base.
Raised sales guidance guarantees a bullish stock reaction
No. Guidance can improve while the stock still reacts poorly if investors focus more on earnings-quality complexity, acquisition costs, or valuation questions than on the top-line signal.
Options pricing gives a clean directional forecast
No. Options pricing reflects uncertainty, hedging demand, and positioning around the event. It does not tell traders where MRK shares must go next.
Bottom line
Merck turned Tuesday, August 4, 2026 into a genuine live-results phase for options traders. Worldwide sales reached USD 16.6 billion, KEYTRUDA and KEYTRUDA QLEX reached USD 8.4 billion, WINREVAIR reached USD 588 million, Animal Health reached USD 1.8 billion, and the company raised its full-year sales range to USD 66.3 billion to USD 67.3 billion.
For options traders, the useful takeaway is not a one-line judgment on whether the quarter was “good” or “bad.” The real takeaway is that Merck gave the market a stronger operating picture than the charge-heavy EPS headline suggests. The next job is to compare the realized stock move and post-earnings volatility reset with how much of that mix the options market had already priced.
This is not financial advice. Options trading involves risk and is not suitable for all investors.
Sources
- SEC filing index for Merck’s August 4, 2026 Form 8-K and attached exhibits (plain-text URL):
https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/0001104659-26-090045-index.htm - SEC-furnished Merck second-quarter 2026 earnings release, Exhibit 99.1 (plain-text URL):
https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_ex99-1.htm - SEC-furnished Merck supplemental exhibit, Exhibit 99.2 (plain-text URL):
https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_ex99-2.htm
